Author, year | Patients (n) | Injection site | Injection dose | Identification rate | Number of SLNs | Localization method |
---|---|---|---|---|---|---|
Liu,2019 [24] | 75 | Intradermally inject at 3,6,9,12 o’clock around the arela | 0.5ml x 4 | 94.67 % (71/75) | 116 | Skin marked |
Li,2019 [23] | 453 | Intradermally inject at 3,6,9,12 o’clock around the arela | 0.6ml x 4 | 98.2 % (445/453) | 765 | Skin marked |
Kenzo,2019 [22] | 75 | Intradermally and subdermally inject at 3,6,9,12 o’clock around the arela | 0.25ml x 8 | 100 % (100/100) | 92 | Skin marked |
Zhong,2018 [19] | 126 | Intradermally inject at outer upper quadrant near the areola | 2ml | 100 % (126/126) | 164 | FNA |
Xie,2015 [18] | 101 | Intradermally inject at outer upper quadrant near the areola | 1.5ml | 97.03 % (98/101) | 115 | Guidewire |
Zhao,2018 [20] | 110 | Intradermally inject at the periareolar area | 0.4ml (One or two additional injections if failed) | 96.4 % (106/110) | 134 | Skin marked |